SCH772984 HCl: Unlocking ERK1/2 Inhibition for Next-Gener...
2025-10-21
Explore how SCH772984 HCl, a leading ERK1/2 inhibitor, is redefining MAPK pathway research by enabling sophisticated resistance modeling in BRAF- and RAS-mutant cancers. Discover distinct mechanistic insights and advanced in vivo strategies that set this comprehensive guide apart.